Biodexa Pharmaceuticals (BDRX) Income - Equity (2013 - 2023)
Biodexa Pharmaceuticals' (BDRX) quarterly Income - Equity came in at $19.6 million in Q4 2023, up 1181.5% quarter-over-quarter from -$1.8 million in Q4 2018.
Powered by 
Analysis
Biodexa Pharmaceuticals (BDRX) Income - Equity (2013 - 2023) Analysis & Trends
Biodexa Pharmaceuticals has disclosed Income - Equity across 6 years of filings, most recently posting $19.6 million for Q4 2023.
- In Q4 2023, Income - Equity changed N/A year-over-year to $19.6 million; the TTM figure through Dec 2023 stood at $19.6 million (changed N/A YoY), while the FY2024 annual figure was $5113.1, down 99.97% from the prior year.
- Income - Equity came in at $19.6 million for Q4 2023 at Biodexa Pharmaceuticals, up from -$1.8 million in the prior quarter.
- In the past five years, Income - Equity ranged from a high of $19.6 million in Q4 2023 to a low of $19.6 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income - Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Biodexa Pharmaceuticals | 52.37 Mn | 41.02 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 19.58 Mn |
| Dec 31, 2018 | -1.81 Mn |
| Dec 31, 2016 | -38.03 Mn |
| Dec 31, 2015 | -19.60 Mn |
| Dec 31, 2014 | -15.35 Mn |
| Dec 31, 2013 | -7.28 Mn |